Application Advance of Flow Cytometry in the CAR-T Cell Therapy--Review.
10.7534/j.issn.1009-2137.2020.01.055
- Author:
Cheng-Gong LI
1
;
Heng MEI
2
;
Yu HU
1
Author Information
1. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430020, Hubei Province, China,The Cell Therapy Clinical Medical Center of Cancer Diseases of Hubei Province. Wuhan 430020, Hubei Province, China.
2. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430020, Hubei Province, China,The Cell Therapy Clinical Medical Center of Cancer Diseases of Hubei Province. Wuhan 430020, Hubei Province, China,E-mail: hmei@hust.edu.cn.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):329-332
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Chimetic antigen receptor T cells (CAR-T) are a kind of novel killer cells derived from autogenous or allogeneic T cells targeting the tumor specific antigens by gene engineering transpormation. The CAR-T cells possess the advantages of high specificity, high efficiency and non-MHC restriction, thus achieving good therapeutic effects in relapsed/refractory hematological tumors and some solid tumors. The process of CAR-T cell preparation includes cell isolation and purification, activation and differentiation, gene modification, in vitro amplification, phenotypic quality control, preservation and reinfusion. In recent years, with the rapid development of flow cytometry, this technology has been widely used in all aspects of CAR-T cell therapy, including pre-treatment screening, in vitro preparation and post-transfusion monitoring, which plays an important role in its innovative optimization.
